Author:
Watanabe Mitsuru,Nakamura Yuri,Sato Shinya,Niino Masaaki,Fukaura Hikoaki,Tanaka Masami,Ochi Hirofumi,Kanda Takashi,Takeshita Yukio,Yokota Takanori,Nishida Yoichiro,Matsui Makoto,Nagayama Shigemi,Kusunoki Susumu,Miyamoto Katsuichi,Mizuno Masanori,Kawachi Izumi,Saji Etsuji,Ohashi Takashi,Shimohama Shun,Hisahara Shin,Nishiyama Kazutoshi,Iizuka Takahiro,Nakatsuji Yuji,Okuno Tatsusada,Ochi Kazuhide,Suzumura Akio,Yamamoto Ken,Kawano Yuji,Tsuji Shoji,Hirata Makoto,Sakate Ryuichi,Kimura Tomonori,Shimizu Yuko,Nagaishi Akiko,Okada Kazumasa,Hayashi Fumie,Sakoda Ayako,Masaki Katsuhisa,Shinoda Koji,Isobe Noriko,Matsushita Takuya,Kira Jun-ichi
Abstract
AbstractHLA genotype-clinical phenotype correlations are not established for multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). We studied HLA-DRB1/DPB1 genotype–phenotype correlations in 528 MS and 165 NMOSD cases using Japan MS/NMOSD Biobank materials. HLA-DRB1*04:05, DRB1*15:01 and DPB1*03:01 correlated with MS susceptibility and DRB1*01:01, DRB1*09:01, DRB1*13:02 and DPB1*04:01 were protective against MS. HLA-DRB1*15:01 was associated with increased optic neuritis and cerebellar involvement and worsened visual and pyramidal functional scale (FS) scores, resulting in higher progression index values. HLA-DRB1*04:05 was associated with younger onset age, high visual FS scores, and a high tendency to develop optic neuritis. HLA-DPB1*03:01 increased brainstem and cerebellar FS scores. By contrast, HLA-DRB1*01:01 decreased spinal cord involvement and sensory FS scores, HLA-DRB1*09:01 decreased annualized relapse rate, brainstem involvement and bowel and bladder FS scores, and HLA-DRB1*13:02 decreased spinal cord and brainstem involvement. In NMOSD, HLA-DRB1*08:02 and DPB1*05:01 were associated with susceptibility and DRB1*09:01 was protective. Multivariable analysis revealed old onset age, long disease duration, and many relapses as independent disability risks in both MS and NMOSD, and HLA-DRB1*15:01 as an independent risk only in MS. Therefore, both susceptibility and protective alleles can influence the clinical manifestations in MS, while such genotype–phenotype correlations are unclear in NMOSD.
Funder
Japan Society for the Promotion of Science
Ministry of Health, Labour and Welfare
Japan Agency for Medical Research and Development
Publisher
Springer Science and Business Media LLC